Regulatory discrepancies and patient-safety risks from the continued marketing of withdrawn medicines in Ecuador, Colombia, and Peru (2014–2025)
Substantial misalignment persists between international and Andean regulatory decisions. The continued regulatory authorization of withdrawn medicines highlights weaknesses in pharmacovigilance and transparency, underscoring the urgent need for regional harmonization and public disclosure of regulatory actions.
Authors
- Enrique Terán (ORCID: https://orcid.org/0000-0001-6979-5655)
- Aida Miranda
- Ariel Moncayo
- Shabnam Santos
- Camila D Lopez
- Fatima Morales
Institutions
- Escuela Superior Politécnica del Chimborazo (EC)
- Universidad San Francisco de Quito (EC)
- Universidad de Sevilla (ES)
- Temple University (US)
Publication Details
- Journal
- Drug Metabolism and Personalized Therapy
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1515/dmpt-2025-0081
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00